Why CVS Caremark’s decision to drop Zepbound could reshape the billion-dollar weight-loss drug war

CVS Health Corporation’s (NYSE: CVS) pharmacy benefit manager CVS Caremark is facing a class action lawsuit filed in the Southern District of New York after it decided to remove Eli Lilly and Company’s (NYSE: LLY) obesity drug Zepbound from its coverage list. The suit, brought by patients earlier this month, accuses the American pharmacy benefit manager of prioritizing financial considerations over medical necessity, particularly for individuals who had already been prescribed Zepbound for chronic weight management and obstructive sleep apnea.

The case underscores rising tensions between payers and pharmaceutical manufacturers in the rapidly expanding GLP-1 therapy segment, where drugs such as Zepbound and Novo Nordisk’s Wegovy are commanding billions in revenue and reshaping the economics of chronic disease treatment. CVS Caremark has defended its formulary strategy as both clinically sound and necessary to curb spiraling costs, but critics describe the move as “nonmedical switching” that undermines physician judgment and patient care.

Why are patients suing CVS Caremark for removing Zepbound from coverage while favoring Wegovy instead?

The lawsuit centers on CVS Caremark’s July 2025 formulary update that excluded Zepbound in favor of Novo Nordisk’s Wegovy. Plaintiffs argue that the decision disregarded clinical evidence showing differences in safety profiles and patient responses between the two drugs. While both belong to the GLP-1 class, Zepbound’s active ingredient, tirzepatide, is a dual GIP and GLP-1 receptor agonist, whereas Wegovy’s semaglutide is GLP-1 only.

For patients with obstructive sleep apnea, Zepbound holds unique regulatory approval, making its removal more consequential. Lawyers representing the patient group have stated that CVS Caremark’s policy violated fiduciary obligations under the Employee Retirement Income Security Act (ERISA) by ignoring individualized treatment needs in favor of cost efficiency. The plaintiffs maintain that this action disrupted stable treatment regimens and placed patients at medical risk.

How does this formulary decision reflect the broader economic pressures around GLP-1 weight-loss drugs?

CVS Health has consistently flagged rising GLP-1 costs as a material challenge for employer-sponsored health plans. According to internal data cited in past quarterly updates, GLP-1 drugs are now among the top five drivers of pharmacy benefit spending in the United States. Zepbound generated $2.31 billion in revenue for Eli Lilly in the first quarter of 2025, while Wegovy posted record sales growth for Novo Nordisk across North America.

By switching its preferred formulary option to Wegovy, CVS Caremark is believed to have negotiated significant rebates and price concessions, creating cost relief for plan sponsors. Institutional investors noted that this is consistent with broader pharmacy benefit manager behavior, where aggressive formulary management is used to rein in specialty drug spending. However, the lawsuit illustrates the backlash when financial priorities appear to override patient-specific medical outcomes.

What concerns do healthcare professionals and patient advocates raise about nonmedical switching in obesity treatment?

Medical professionals have expressed reservations about the implications of the CVS Caremark decision. Endocrinologists and obesity specialists highlight that while both Zepbound and Wegovy can produce weight reduction, not all patients respond identically. Some tolerate one drug better than the other due to gastrointestinal side effects, dosing schedules, or efficacy profiles.

Patient advocates warn that formulary exclusions amount to nonmedical switching, where insurer or PBM decisions—not physicians—determine continuity of care. The Wall Street Journal reported on patients who had achieved meaningful weight loss and symptom relief with Zepbound but were compelled to switch therapies abruptly, raising fears of weight regain or destabilized chronic conditions. These real-world concerns amplify the debate over whether payer strategies are aligned with long-term healthcare outcomes.

How have Eli Lilly and CVS Health stocks responded to the lawsuit and coverage change?

The financial markets quickly reacted to CVS Caremark’s exclusion decision earlier this summer. Shares of Eli Lilly dropped more than 5 percent in the days following the July announcement, reflecting concerns that payer resistance could limit the total addressable market for Zepbound. Even though Lilly’s earnings beat analyst expectations, with double-digit revenue growth from GLP-1 therapies, the CVS decision dampened sentiment about the sustainability of its market dominance.

On September 5, 2025, Eli Lilly stock closed at USD 727.21, down 2.12 percent on the day, with trading volume approaching 3.9 million shares. CVS Health ended slightly higher at USD 73.78, posting only marginal gains. Institutional sentiment suggests a divergence: some investors remain bullish on Eli Lilly’s long-term GLP-1 leadership, while others highlight the risk of future payer pushback and increased formulary competition.

Market observers also point to potential shifts in pharmacy benefit manager regulation. Policymakers have previously scrutinized PBM practices for opacity in rebate structures and formulary exclusions, and this lawsuit could reinvigorate calls for transparency reforms.

What are the implications of the case for future payer-pharma dynamics in the GLP-1 segment?

Analysts suggest the outcome of this lawsuit may have lasting consequences on payer-pharma relations. If courts rule in favor of plaintiffs, PBMs may need to revise exception processes and demonstrate more transparent rationale for exclusions. Conversely, a CVS Caremark win would reinforce payer leverage in dictating formulary design.

For Eli Lilly, the setback underscores the need to emphasize Zepbound’s differentiated value proposition—not only in weight management but also in comorbidities such as obstructive sleep apnea and type 2 diabetes. If physicians and patients continue to perceive Zepbound as clinically superior in certain cases, pressure will mount on payers to restore coverage. Novo Nordisk, meanwhile, could consolidate its advantage if Wegovy becomes entrenched as the preferred GLP-1 option across major PBM formularies.

What is the future outlook for patients, investors, and policymakers watching this case?

For patients, the lawsuit’s resolution could influence access to life-changing obesity therapies. The growing prevalence of obesity—affecting more than 40 percent of U.S. adults—means demand for GLP-1 drugs will remain strong. Broader insurance coverage policies, including exceptions for medically necessary cases, will be key in shaping outcomes.

For investors, the CVS-Lilly dispute illustrates the volatility that payer decisions can inject into pharmaceutical valuations. Buy-side sentiment currently skews cautious, with some hedge funds trimming positions in Eli Lilly to hedge against payer risk, while long-only institutions maintain conviction in its diversified pipeline.

Policymakers are likely to monitor developments closely as PBM practices face mounting bipartisan scrutiny. Calls for legislation that mandates transparency in rebate flows, formulary exclusions, and appeal timelines could intensify if cases like this one draw national attention.